Skip to main content
SpringerLink
Log in

CML-Therapie mal aussetzen?

  • Literatur kompakt
  • Leukämien und Lymphome
  • Published:
Im Focus Onkologie Aims and scope

Die Leitlinien empfehlen, die Therapie der chronischen myeloischen Leukämie (CML) mit Tyrosinkinaseinhibitoren (TKI) bei Ansprechen ohne Absetzen fortzuführen. Einige Patienten bleiben aber nach Absetzen stabil.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  • Ross DM et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Blood. 2013;122(4):515–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Frederike Klein

Authors
  1. Frederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klein, F. CML-Therapie mal aussetzen?. Im Focus Onkologie 16, 22 (2013). https://doi.org/10.1007/s15015-013-0640-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-013-0640-6

Search

Navigation